TILE
Interface, Inc. NASDAQ Listed Apr 14, 1983$27.55
Mkt Cap $1.6B
52w Low $18.74
53.8% of range
52w High $35.11
50d MA $27.29
200d MA $27.83
P/E (TTM)
14.0x
EV/EBITDA
9.4x
P/B
1.4x
Debt/Equity
0.2x
ROE
18.1%
P/FCF
13.7x
RSI (14)
—
ATR (14)
—
Beta
1.96
50d MA
$27.29
200d MA
$27.83
Avg Volume
573.8K
Interface, Inc., a modular flooring company, designs, produces, and sells modular carpet products primarily in the Americas, Europe, and the Asia-Pacific. The company offers modular carpets under the Interface and FLOR brand names; carpet tiles under the GlasBacRE name for use in commercial interiors, including offices, healthcare facilities, airports, educational and other institutions, hospitality spaces, and retail facilities, as well as residential interiors; modular resilient flooring products; rubber flooring under the norament and noraplan brand names; and luxury vinyl tile products. It also produces and sells an adapted version of its carpet tile for the healthcare facilities market; and two-meter roll goods that are structure-backed for use in education, healthcare, and government markets, as well as carpet replacement, installation, and maintenance services. In addition, the company sells and licenses a proprietary antimicrobial chemical compound under the Intersept name for use in interior finishes; sells TacTiles, a carpet tile installation system, as well as various adhesives and products; and provides turnkey project management services for global accounts and other customers through its InterfaceSERVICES business. It sells its products directly to end-users, as well as indirectly through independent contractors or distributors, and FLOR line of products through Internet sales and commercial sales force. The company has product showrooms or design studios in the United States, Canada, Mexico, England, France, Germany, Spain, the Netherlands, India, Australia, Norway, the United Arab Emirates, Russia, Singapore, Hong Kong, Thailand, China, and others. Interface, Inc. was incorporated in 1973 and is headquartered in Atlanta, Georgia.
1280 West Peachtree Street NW · Atlanta, GA 30309 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 8, 2026 | TNS | 0.33 | 0.41 | +24.2% | — | — | — | — | — | — | — | — |
| Feb 24, 2026 | TNS | 0.40 | 0.49 | +22.5% | 31.88 | -0.3% | -0.3% | -0.8% | -1.2% | -4.7% | -7.5% | — |
| Oct 31, 2025 | TNS | 0.46 | 0.61 | +32.6% | 24.90 | +0.0% | +3.9% | +3.9% | +4.9% | +3.5% | +3.5% | — |
| Aug 1, 2025 | TNS | 0.47 | 0.60 | +27.7% | 24.61 | -1.3% | +2.6% | +3.5% | +4.5% | +1.1% | +1.1% | — |
| May 2, 2025 | TNS | 0.20 | 0.25 | +25.0% | 19.23 | -1.2% | -0.4% | +2.0% | +3.3% | +6.2% | +7.4% | — |
| Feb 25, 2025 | TNS | 0.29 | 0.34 | +17.2% | 18.87 | +0.9% | +5.0% | +3.9% | +7.2% | +1.2% | -0.6% | — |
| Nov 1, 2024 | TNS | 0.34 | 0.48 | +41.2% | 23.24 | +0.1% | +1.1% | +3.8% | +6.4% | +5.4% | +7.7% | — |
| Aug 2, 2024 | TNS | 0.28 | 0.40 | +42.9% | 17.34 | -7.8% | -3.3% | -3.7% | -6.3% | -5.0% | -5.2% | — |
| May 3, 2024 | TNS | 0.12 | 0.24 | +100.0% | 17.39 | +0.3% | -5.5% | -6.9% | -8.3% | -8.5% | -6.7% | — |
| Feb 27, 2024 | TNS | 0.23 | 0.41 | +78.3% | 15.18 | -0.1% | +1.5% | +3.6% | +2.9% | +0.2% | -0.6% | — |
| Nov 3, 2023 | TNS | 0.25 | 0.28 | +12.0% | 9.58 | +0.0% | -0.8% | -2.3% | -2.9% | -5.2% | -2.4% | — |
| Aug 4, 2023 | TNS | 0.19 | 0.25 | +31.6% | 9.77 | +2.4% | +4.9% | +5.6% | +6.1% | +5.1% | +5.8% | — |
| May 5, 2023 | AMC | 0.11 | 0.07 | -36.4% | 7.46 | -0.8% | -4.6% | -6.4% | -6.6% | -6.8% | -7.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 17 | Barrington Research | Maintains | Outperform → Outperform | — | $26.85 | $27.49 | +2.4% | +5.0% | +5.8% | +4.8% | +5.3% | +4.1% |
| Jan 23 | Barrington Research | Maintains | Outperform → Outperform | — | $31.84 | $31.79 | -0.2% | -2.1% | -1.4% | -2.0% | -1.3% | -0.8% |
| Oct 31 | Barrington Research | Maintains | Outperform → Outperform | — | $26.67 | $28.17 | +5.6% | -6.6% | -3.0% | -3.0% | -2.1% | -3.3% |
| Oct 15 | Barrington Research | Maintains | Outperform → Outperform | — | $26.60 | $26.79 | +0.7% | +2.4% | +2.3% | +2.1% | +4.3% | +6.0% |
| Aug 29 | Barrington Research | Maintains | Outperform → Outperform | — | $26.74 | $26.82 | +0.3% | -0.1% | -0.9% | -0.2% | +4.3% | +5.4% |
| Aug 1 | Barrington Research | Maintains | Outperform → Outperform | — | $20.62 | $23.97 | +16.2% | +19.4% | +22.5% | +23.5% | +24.7% | +20.7% |
| Jul 22 | Barrington Research | Maintains | Outperform → Outperform | — | $20.39 | $20.39 | +0.0% | +1.6% | +3.6% | +1.4% | +2.5% | +2.7% |
| May 2 | Barrington Research | Maintains | Outperform → Outperform | — | $18.85 | $20.03 | +6.3% | +2.0% | +1.6% | +4.0% | +5.4% | +8.4% |
| Apr 15 | Barrington Research | Maintains | Outperform → Outperform | — | $18.79 | $18.79 | +0.0% | +0.9% | -0.7% | -1.1% | -4.8% | -3.3% |
| Feb 25 | Barrington Research | Maintains | Outperform → Outperform | — | $21.31 | $19.80 | -7.1% | -11.4% | -7.0% | -8.0% | -5.1% | -10.4% |
| Jan 28 | Barrington Research | Maintains | Outperform → Outperform | — | $24.39 | $24.37 | -0.1% | +0.5% | +0.1% | +3.0% | +1.5% | -3.3% |
| Dec 11 | Barrington Research | Maintains | Outperform → Outperform | — | $25.72 | $26.15 | +1.7% | +2.7% | +2.4% | +1.6% | +1.5% | +0.1% |
| Nov 1 | Barrington Research | Maintains | Outperform → Outperform | — | $17.47 | $20.42 | +16.9% | +33.0% | +34.5% | +38.1% | +41.6% | +40.2% |
| Sep 20 | Barrington Research | Maintains | Outperform → Outperform | — | $19.00 | $18.88 | -0.6% | -0.2% | -2.4% | -2.6% | -3.5% | -3.0% |
| Aug 2 | Barrington Research | Maintains | Outperform → Outperform | — | $16.54 | $17.00 | +2.8% | +4.8% | +1.4% | +1.0% | -1.8% | -0.4% |
| Jun 17 | Barrington Research | Maintains | Outperform → Outperform | — | $14.63 | $14.61 | -0.1% | +1.7% | +2.1% | -0.1% | +0.3% | +1.9% |
| May 3 | Barrington Research | Maintains | Outperform → Outperform | — | $15.86 | $17.70 | +11.6% | +9.6% | +3.6% | +2.1% | +0.6% | +0.3% |
| Feb 28 | Truist | Maintains | Hold → Hold | — | $15.18 | $15.17 | -0.1% | +1.5% | +3.6% | +2.9% | +0.2% | -0.6% |
| Aug 7 | Truist | Maintains | Hold → Hold | — | $9.77 | $10.00 | +2.4% | +4.9% | +5.6% | +6.1% | +5.1% | +5.8% |
| May 8 | Truist | Maintains | Hold → Hold | — | $7.46 | $7.40 | -0.8% | -4.6% | -6.4% | -6.6% | -6.8% | -7.2% |
| Mar 1 | Longbow Research | Upgrade | Neutral → Buy | — | $8.82 | $9.10 | +3.2% | +5.6% | +8.0% | +6.3% | +0.0% | -1.4% |
| Feb 22 | Truist | Downgrade | Buy → Hold | — | $11.14 | $10.15 | -8.9% | -23.2% | -21.9% | -21.0% | -20.0% | -20.8% |
| Mar 2 | Raymond James | Maintains | Outperform → Outperform | — | $13.99 | $14.06 | +0.5% | +5.3% | +6.1% | +0.4% | -6.3% | -6.5% |
| Nov 8 | Raymond James | Upgrade | Market Perform → Outperform | — | $15.99 | $16.53 | +3.4% | +4.3% | +2.9% | +0.7% | +3.0% | +3.9% |
| Aug 10 | Truist | Maintains | Buy → Buy | — | $8.49 | $8.39 | -1.2% | -3.9% | -1.4% | -3.1% | -3.2% | -1.6% |
| May 12 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $8.58 | $8.57 | -0.1% | -7.8% | -11.2% | -13.6% | -12.6% | -0.5% |
| May 11 | Nomura Instinet | Maintains | Buy → Buy | — | $9.02 | $9.22 | +2.2% | -4.9% | -12.3% | -15.5% | -17.8% | -16.9% |
| May 11 | Nomura | Maintains | Buy → Buy | — | $9.02 | $9.22 | +2.2% | -4.9% | -12.3% | -15.5% | -17.8% | -16.9% |
| Apr 17 | Nomura | Maintains | Buy → Buy | — | $8.17 | $8.59 | +5.1% | +7.7% | +2.9% | +0.1% | -4.0% | +0.4% |
| Apr 16 | SunTrust Robinson Humphrey | Maintains | Buy → Buy | — | $8.44 | $8.42 | -0.2% | -3.2% | +4.3% | -0.4% | -3.1% | -7.1% |
| Feb 27 | Stifel Nicolaus | Maintains | Hold → Hold | — | $16.16 | $16.48 | +2.0% | -5.0% | -9.7% | -9.6% | -11.8% | -9.5% |
| Feb 27 | Raymond James | Upgrade | Underperform → Market Perform | — | $16.16 | $16.48 | +2.0% | -5.0% | -9.7% | -9.6% | -11.8% | -9.5% |
| Feb 25 | Stifel Nicolaus | Maintains | Hold → Hold | — | $16.10 | $16.08 | -0.1% | -2.5% | +0.4% | -4.6% | -9.4% | -9.3% |
| Feb 25 | Stifel | Maintains | Hold → Hold | — | $16.10 | $16.08 | -0.1% | -2.5% | +0.4% | -4.6% | -9.4% | -9.3% |
| Oct 28 | Longbow Research | Downgrade | Buy → Neutral | — | $16.45 | $16.14 | -1.9% | +2.6% | +2.9% | -0.7% | +1.1% | +1.9% |
| Jan 7 | Nomura | Maintains | Buy → Buy | — | $14.68 | $14.71 | +0.2% | +1.8% | +3.3% | +4.8% | +6.0% | +6.4% |
| Aug 14 | Longbow Research | Upgrade | Neutral → Buy | — | $22.40 | $24.50 | +9.4% | +2.7% | +1.1% | +1.8% | +2.2% | +3.1% |
| Oct 27 | Nomura | Maintains | Buy → Buy | — | $22.80 | $22.85 | +0.2% | +2.0% | -0.4% | +0.0% | -0.4% | -0.4% |
| Apr 12 | Nomura | Maintains | Buy → Buy | — | $19.05 | $19.30 | +1.3% | -1.3% | -2.4% | -0.5% | -1.0% | -0.5% |
| Nov 4 | Seaport Global | Maintains | Buy → Buy | — | $15.35 | $15.80 | +2.9% | +2.9% | +5.9% | +5.5% | +8.5% | +10.4% |
| Jun 24 | Raymond James | Downgrade | Market Perform → Underperform | — | $17.20 | $15.82 | -8.0% | -8.8% | -13.7% | -14.7% | -12.7% | -11.3% |
| May 5 | Longbow Research | Downgrade | Buy → Neutral | — | $16.67 | $16.13 | -3.2% | -2.2% | -0.7% | -1.1% | -0.8% | -2.1% |
| Apr 27 | Stifel | Downgrade | Buy → Hold | — | $18.48 | $17.47 | -5.5% | -5.7% | -5.2% | -7.9% | -7.6% | -9.3% |
| Apr 27 | Stifel Nicolaus | Downgrade | Buy → Hold | — | $18.48 | $17.47 | -5.5% | -5.7% | -5.2% | -7.9% | -7.6% | -9.3% |
| Apr 7 | Barclays | Downgrade | Equal Weight → Underweight | — | $18.48 | $17.59 | -4.8% | -2.5% | -4.3% | -4.9% | -4.7% | -0.8% |
| Feb 25 | Barclays | Downgrade | Overweight → Equal Weight | — | $17.40 | $15.44 | -11.3% | -12.0% | -10.1% | -8.6% | -7.8% | -7.0% |
| Jan 20 | Barclays | Maintains | Overweight → Overweight | — | $16.10 | $15.81 | -1.8% | +0.0% | -2.4% | -0.9% | -1.5% | +1.3% |
| Oct 30 | Macquarie | Maintains | Outperform → Outperform | — | $19.50 | $19.88 | +1.9% | +0.3% | +1.6% | +0.8% | +1.1% | +1.4% |
| Oct 30 | Stifel | Upgrade | Hold → Buy | — | $19.50 | $19.88 | +1.9% | +0.3% | +1.6% | +0.8% | +1.1% | +1.4% |
| Oct 30 | Stifel Nicolaus | Upgrade | Hold → Buy | — | $19.50 | $19.88 | +1.9% | +0.3% | +1.6% | +0.8% | +1.1% | +1.4% |
No insider trades available.
8-K · 2.02
!! High
Interface, Inc. -- 8-K 2.02: Earnings Results
Interface, Inc. reported Q1 2026 earnings results on May 8, 2026, with detailed financial performance metrics available in the attached earnings release for investor review.
May 8
8-K · 7.01
! Medium
Interface Inc -- 8-K 7.01: Regulation FD Disclosure
Interface Inc disclosed a presentation to investors via Regulation FD, providing updates on company performance and strategy without triggering selective disclosure violations for shareholders.
Feb 24
Data updated apr 27, 2026 4:48am
· Source: massive.com